Efficacy of infliximab in treatment-naïve patients with stricturing small bowel Crohn’s disease

Abstract

Objectives

The efficacy of infliximab in treatment-naïve patients with stricturing small bowel Crohn’s disease (CD) has not been well studied. We aimed to evaluate the efficacy of infliximab in these patients.

Materials and methods

This was a retrospective study of all consecutive treatment-naïve patients with newly diagnosed CD with small bowel stricture who started regular infliximab therapy in Nanfang Hospital between January 2015 and December 2019. An effective infliximab therapy was defined as infliximab continuation without the use of steroids, new biologics, endoscopic interventions or intestinal surgery.

Results

Seventy-nine patients were included. After a median 38 months follow-up, an effective infliximab therapy was achieved in 37 patients. Long diagnostic delay (hazard ratio [HR] 0.38, 95% confidence interval [CI] 0.19–0.78; p= .008), pre-stenotic dilatation (HR 0.17, 95%CI 0.09–0.35; p < .001), long segmental stricture (HR 0.20, 95%CI 0.10–0.41; p < .001), and penetrating disease (HR 0.22, 95%CI 0.10–0.49; p < .001) were negatively correlated with an effective infliximab therapy.

Conclusions

Infliximab is effective in nearly 50% of treatment-naïve patients with CD with small bowel stricture, and an effective therapy is more likely to be achieved in patients without long diagnostic delay, pre-stenotic dilatation, long segmental stricture or penetrating disease.

Keywords:

• Crohn’s disease
• infliximab
• small bowel
• stricture
• treatment-naïve

Disclosure of interest

The authors report no conflict of interest.

Additional information

Funding

This work was supported by the National Natural Science Foundation of China [grant number 32000076].